RNase Control Market Size & Share, by Product Type (Recombinant, Non-Recombinant); Application (RNase Control that Inhibits A Family, RNase Control that Inhibits Other Than A Family); End-User (Research Institutes, Laboratories, Health Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036
Merck & Co. partnered with a biotechnology company, Orna Therapeutics to find, create, and market cancer and infectious illness vaccines and treatments. Furthermore, by this partnership, Orna Therapeutics intends to maintain ownership of its oRNA-LNP technology platform and pursue further development of programs related to genetic diseases and oncology.
Eli Lilly and Company announced a collaboration with ProQR Therapeutics N.V. to utilize ProQR's unique Axiomer RNA editing platform to identify, create, and market novel genetic medications and investigate further uses for the Axiomer platform to provide patients with illnesses that have a high unmet medical need.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5512
Published Date: Jan 05, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Growing cases of HIV across the globe and the growing advancements in RNase technology are the major factors driving the growth of the market.
The market size of RNase control is anticipated to attain a CAGR of 8% during the forecast period, i.e., 2024-2036.
The major players in the market are QIAGEN, Merck & Co., Beyotime, NEB, Promega, BioVision, Rockland Immunochemicals, AG Scientific, Jena Bioscience, and others.
The recombinant segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.